Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers Fri, 17 Nov 2017 14:26:00 +0000 Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.
ETFs with exposure to Revance Therapeutics, Inc. : November 13, 2017 Mon, 13 Nov 2017 18:08:46 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Revance Therapeutics, Inc. Here are 5 ETFs with the largest exposure to RVNC-US. Comparing the performance and risk of Revance Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : November 10, 2017 Fri, 10 Nov 2017 12:57:37 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Revance Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Tue, 07 Nov 2017 13:02:20 +0000 Categories: Yahoo FinanceGet free summary analysis Revance Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Revance Therapeutics, Inc. – Johnson & Johnson and Biogen Inc. (JNJ-US and BIIB-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.08 million, ... Read more
(Read more...)
Revance reports 3Q loss Thu, 02 Nov 2017 22:50:15 +0000 The Newark, California-based company said it had a loss of $1.01 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : October 31, 2017 Tue, 31 Oct 2017 16:19:41 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Revance Therapeutics, Inc. a score of 17. Our analysis is based on comparing Revance Therapeutics, Inc. with the following peers – Valeant Pharmaceuticals International Inc, MediciNova, Inc., Johnson & Johnson, Biogen Inc., Ionis Pharmaceuticals, Inc. and Tenax Therapeutics, Inc. (VRX-US, MNOV-US, JNJ-US, BIIB-US, IONS-US and TENX-US). Investment ... Read more
(Read more...)
ETFs with exposure to Revance Therapeutics, Inc. : October 31, 2017 Tue, 31 Oct 2017 15:49:55 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Revance Therapeutics, Inc. Here are 5 ETFs with the largest exposure to RVNC-US. Comparing the performance and risk of Revance Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : October 30, 2017 Mon, 30 Oct 2017 12:11:07 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Revance Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Accum/Dist: 1.32 (median winner: 1.53)
Group Action: 2 (median winner: 20)
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.